Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cynata Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Medibio jumps 50pc on Phase 1 results; Cann doubles cannabis harvest
Experts
Dr Boreham’s Crucible: Is this a case of what’s good for Mesoblast is good for Cynata?
News
CLOSING BELL: Welcome to the ASX, where our motto is ‘chin up, mate… it could’ve been worse’
Health & Biotech
ASX Health Stocks: Pharmaxis and Aroa lift on FDA news, Cynata to commence Phase 2 trial
News
Closing Bell: RBA Board finally bottles out, snapping its 10-month winning streak
Health & Biotech
The chances of Phase 3 success, and the ASX health stocks that are close to a home run
Health & Biotech
Which ASX stocks are on the path from FDA to clinical trial in 2023?
Health & Biotech
ASX Health Stocks: Patent updates from Cynata and Proteomics; Ramsay sees good times ahead
Health & Biotech
ASX Biotech Stocks: HitIQ nabs landmark deal with Premier League for its concussion management tech
Health & Biotech
ASX Health Stocks: Patrys crosses brain barrier, opens up possibilities for its deoxymab antibody
Health & Biotech
ASX Health Stocks: Cynata races ahead after getting green light for diabetic foot ulcer clinical trial
Health & Biotech
ASX Health Stocks: Botanix seeks nod from US FDA; PainChek goes big in Japan
Health & Biotech
ASX Health Stocks: Avita tumbles 16pc as RECELL study results disappoint investors
Health & Biotech
ASX Health Stocks: Another Aussie biotech gets attention in the US with a pending patent
Health & Biotech
ASX Health Stocks: Cynata gets FDA green light for Phase 2, share price up 10pc
Health & Biotech
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
Health & Biotech
